- The FDA has accepted for review Daré Bioscience Inc's DARE marketing application for DARE-BV1 for bacterial vaginosis.
- Under the priority review, the target goal date is December 7.
- DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
- The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
- Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in